About Forzetsn Pharma Solutions

Nate earned his PhD under the direction of Koji Nakanishi at Columbia University where he received broad training in organic synthesis, protein biochemistry and biophysics related to the chemistry of vertebrate vision. During this time he identified a series of compounds useful in the treatment of age related macular degeneration and Stargardt’s disease (affecting central vision), one of which is currently in Phase III clinical trials. Nate has 20+ years of experience in R&D management, leading teams toward the discovery of small and large molecules (ADCs) for the treatment of cancer. Nate served as VP, Head of Chemistry and Platform technology at Orum Therapeutics (clinical stage series B biotech), leading an international team in medicinal chemistry, bioconjugation, protein engineering, physics-based modeling, structural biology, analytical sciences and DMPK, leading to 2 accepted INDs. Most recently, Nate led the discovery and early development at Modifi Bio, a preclinical biotechnology company acquired by Merck and Co. Nate is an experienced and creative drug hunter who will use every available resource to drive your drug discovery programs forward. His work ethic and passion came in large part from the endless encouragement from his father who always said "Keep going"! (Forzetsn in Yiddish)

CV